BR9914215A - Antagonistas de mglur5 para o tratamento da dor e da ansiedade - Google Patents
Antagonistas de mglur5 para o tratamento da dor e da ansiedadeInfo
- Publication number
- BR9914215A BR9914215A BR9914215-5A BR9914215A BR9914215A BR 9914215 A BR9914215 A BR 9914215A BR 9914215 A BR9914215 A BR 9914215A BR 9914215 A BR9914215 A BR 9914215A
- Authority
- BR
- Brazil
- Prior art keywords
- pain
- treatment
- antagonists
- anxiety
- mglur5
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 4
- 208000019901 Anxiety disease Diseases 0.000 title abstract 3
- 230000036506 anxiety Effects 0.000 title abstract 3
- 101150087728 Grm5 gene Proteins 0.000 abstract 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229940124807 mGLUR antagonist Drugs 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
Patente de Invenção: <B>"ANTAGONISTAS DE MGLUR5 PARA O TRATAMENTO DA DOR E DA ANSIEDADE"<D>. A invenção refere-se ao uso de antagonistas seletivos do mGluR5 para o tratamento da dor e da ansiedade, e o uso de antagonistas de mGluR para o tratamento da dor, em que o efeito analgésico é conseguido através da interação do referido antagonista de forma primária ou de forma predominante aos receptores de mGluR periféricos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9821503.1A GB9821503D0 (en) | 1998-10-02 | 1998-10-02 | Organic compounds |
| US22081398A | 1998-12-23 | 1998-12-23 | |
| PCT/EP1999/007239 WO2000020001A1 (en) | 1998-10-02 | 1999-09-30 | Mglur5 antagonists for the treatment of pain and anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9914215A true BR9914215A (pt) | 2001-07-03 |
Family
ID=26314451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9914215-5A BR9914215A (pt) | 1998-10-02 | 1999-09-30 | Antagonistas de mglur5 para o tratamento da dor e da ansiedade |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1117403B1 (pt) |
| JP (1) | JP2002526408A (pt) |
| KR (1) | KR20010088832A (pt) |
| CN (1) | CN1187048C (pt) |
| AT (1) | ATE255894T1 (pt) |
| AU (1) | AU765644B2 (pt) |
| BR (1) | BR9914215A (pt) |
| CA (1) | CA2345137A1 (pt) |
| DE (1) | DE69913548T2 (pt) |
| DK (1) | DK1117403T3 (pt) |
| ES (1) | ES2213389T3 (pt) |
| HU (1) | HUP0200553A3 (pt) |
| ID (1) | ID29095A (pt) |
| IL (2) | IL142047A0 (pt) |
| NO (1) | NO20011440L (pt) |
| NZ (1) | NZ510743A (pt) |
| PL (1) | PL202906B1 (pt) |
| PT (1) | PT1117403E (pt) |
| RU (1) | RU2232017C2 (pt) |
| SK (1) | SK4382001A3 (pt) |
| WO (1) | WO2000020001A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0005700D0 (en) * | 2000-03-09 | 2000-05-03 | Glaxo Group Ltd | Therapy |
| BR0116378A (pt) | 2000-12-22 | 2003-10-28 | Hoffmann La Roche | Derivados de tetraìdro-(benzo ou tieno)- azepinas pirazina e triazina como antagonistas de mglur 1 |
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| SE0303419D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 11 |
| SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| PT2083811T (pt) | 2006-11-22 | 2017-01-23 | Clinical Res Ass Llc | Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012054724A1 (en) | 2010-10-21 | 2012-04-26 | Massachusetts Institute Of Technology | Methods of treating seizure disorders |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| EP2557183A1 (de) | 2011-08-12 | 2013-02-13 | Siemens Aktiengesellschaft | Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts |
| EP2852591A1 (en) | 2012-05-03 | 2015-04-01 | Novartis AG | L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| MA42508B1 (fr) | 2015-06-03 | 2020-05-29 | Hoffmann La Roche | Dérivés d'éthynyle |
| AU2018310881C1 (en) | 2017-07-31 | 2021-12-16 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
| EP3459939A1 (en) | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
-
1999
- 1999-09-30 CN CNB998117110A patent/CN1187048C/zh not_active Expired - Fee Related
- 1999-09-30 DE DE69913548T patent/DE69913548T2/de not_active Revoked
- 1999-09-30 KR KR1020017004152A patent/KR20010088832A/ko not_active Application Discontinuation
- 1999-09-30 BR BR9914215-5A patent/BR9914215A/pt not_active Application Discontinuation
- 1999-09-30 WO PCT/EP1999/007239 patent/WO2000020001A1/en not_active Application Discontinuation
- 1999-09-30 AU AU61984/99A patent/AU765644B2/en not_active Ceased
- 1999-09-30 AT AT99948905T patent/ATE255894T1/de active
- 1999-09-30 ES ES99948905T patent/ES2213389T3/es not_active Expired - Lifetime
- 1999-09-30 CA CA002345137A patent/CA2345137A1/en not_active Abandoned
- 1999-09-30 HU HU0200553A patent/HUP0200553A3/hu unknown
- 1999-09-30 RU RU2001111868/14A patent/RU2232017C2/ru not_active IP Right Cessation
- 1999-09-30 PT PT99948905T patent/PT1117403E/pt unknown
- 1999-09-30 EP EP99948905A patent/EP1117403B1/en not_active Revoked
- 1999-09-30 NZ NZ510743A patent/NZ510743A/en unknown
- 1999-09-30 DK DK99948905T patent/DK1117403T3/da active
- 1999-09-30 JP JP2000573360A patent/JP2002526408A/ja active Pending
- 1999-09-30 ID IDW20010730A patent/ID29095A/id unknown
- 1999-09-30 PL PL346876A patent/PL202906B1/pl not_active IP Right Cessation
- 1999-09-30 SK SK438-2001A patent/SK4382001A3/sk unknown
- 1999-09-30 IL IL14204799A patent/IL142047A0/xx active IP Right Grant
-
2001
- 2001-03-15 IL IL142047A patent/IL142047A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011440A patent/NO20011440L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL202906B1 (pl) | 2009-08-31 |
| HUP0200553A3 (en) | 2002-11-28 |
| KR20010088832A (ko) | 2001-09-28 |
| JP2002526408A (ja) | 2002-08-20 |
| WO2000020001A1 (en) | 2000-04-13 |
| AU6198499A (en) | 2000-04-26 |
| SK4382001A3 (en) | 2001-08-06 |
| CA2345137A1 (en) | 2000-04-13 |
| ID29095A (id) | 2001-07-26 |
| DE69913548D1 (de) | 2004-01-22 |
| EP1117403A1 (en) | 2001-07-25 |
| PT1117403E (pt) | 2004-04-30 |
| DK1117403T3 (da) | 2004-04-13 |
| DE69913548T2 (de) | 2004-09-23 |
| EP1117403B1 (en) | 2003-12-10 |
| AU765644B2 (en) | 2003-09-25 |
| ES2213389T3 (es) | 2004-08-16 |
| NZ510743A (en) | 2003-10-31 |
| IL142047A (en) | 2007-09-20 |
| RU2232017C2 (ru) | 2004-07-10 |
| HUP0200553A2 (hu) | 2002-07-29 |
| IL142047A0 (en) | 2002-03-10 |
| NO20011440L (no) | 2001-05-15 |
| ATE255894T1 (de) | 2003-12-15 |
| NO20011440D0 (no) | 2001-03-21 |
| CN1187048C (zh) | 2005-02-02 |
| CN1321087A (zh) | 2001-11-07 |
| PL346876A1 (en) | 2002-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9914215A (pt) | Antagonistas de mglur5 para o tratamento da dor e da ansiedade | |
| NO20030213D0 (no) | Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi | |
| EE200000778A (et) | 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena | |
| DE60113100D1 (de) | Emulsion und wasserabstossende zusammensetzung | |
| DE60118908D1 (de) | Behandlung von mineralischen stoffen | |
| DZ3373A1 (fr) | Catalyseur et procede de preparation d'hydrocarbures | |
| AR025883A1 (es) | Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos | |
| EE200100243A (et) | 5HT1 retseptori agonistid ja metoklopramiid migreeni raviks | |
| BR0214481A (pt) | Método e composição para potenciação de um analgésico opiáceo | |
| EA200401584A1 (ru) | Способ содействия прекращению курения | |
| FR2815541B1 (fr) | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique | |
| ATE266420T1 (de) | Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält | |
| BR9808302A (pt) | O uso de levobupivacaìna na cirurgia pediátrica | |
| BR9915879A (pt) | Antagonista de receptor de vitronectina | |
| EE200100553A (et) | Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks | |
| BR0006269A (pt) | Aplicação de dialquilpolissulfetos para o amassamento de borrachas naturais e de sìntese | |
| BR9804749A (pt) | Tratamento de purido. | |
| BR9808299A (pt) | O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca | |
| CY1108053T1 (el) | Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου | |
| BR0210612A (pt) | Composição auxiliar de enxágue contendo um bio-polipeptìdeo | |
| NO20041595L (no) | Ny kombinasjon bestaende av en PDE4 inhibitor eller en PDE3/4 inhibitor i kombinasjon med en leukotrienreseptorantagonist for behandling av luftveislidelser | |
| DE60100043D1 (de) | Zusammensetzung von Poly-1-Butenharz und die Zusammensetzung enthaltendes Wasserrohr | |
| BR0313230A (pt) | Uso de carboxamidas para o tratamento de tinido | |
| FR2814367B1 (fr) | Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies | |
| NO20001894D0 (no) | Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL.8: A61K 31/44, A61K 31/4402, A61K 31/4418, A61P 25/00, A61P 25/04, A61P 25/18, A61P 25/24, A61P 29/00, A61P 43/00 Ipc: A61K 31/44 (2007.10), A61K 31/4402 (2007.10), A61K |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE INCIDE NO ARTIGO 8O, 11 E 25 DA LPI ( LEI 9279/96 ) |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |